| 0.66 0 (0%) | 01-17 15:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.93 | 1-year : | 1.09 |
| Resists | First : | 0.8 | Second : | 0.93 |
| Pivot price | 0.71  |
|||
| Supports | First : | 0.32 | Second : | 0.02 |
| MAs | MA(5) : | 0.66 |
MA(20) : | 0.72 |
| MA(100) : | 0.73 |
MA(250) : | 0.84 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 87.9 |
| RSI | RSI(14): 24.8 | |||
| 52-week | High : | 1.02 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FRTX ] has closed above bottom band by 13.2%. Bollinger Bands are 104.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.66 - 0.67 | 0.67 - 0.67 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.65 - 0.66 | 0.66 - 0.67 |
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Mon, 17 Jun 2024
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company - Yahoo Finance
Mon, 13 Nov 2023
Fresh Tracks expects to distribute $5M to $7M to shareholders after dissolution - BizWest
Wed, 20 Sep 2023
Fresh Tracks, Histogen to Shutter Businesses in Absence of Viable Options - BioSpace
Tue, 19 Sep 2023
Fresh Tracks to dissolve after hunt for buyer comes up empty - Fierce Biotech
Fri, 25 Aug 2023
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole - InvestorPlace
Mon, 14 Aug 2023
Cash-strapped Fresh Tracks pauses R&D run as search for a buyer continues - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 30.2 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | -71.2 % |
| Operating Margin | -79.5 % |
| Return on Assets (ttm) | -36.4 % |
| Return on Equity (ttm) | -66.5 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.34 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 0.49 |
| Price to Cash Flow | -0.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|